On January 2, 2015, Fiser, Inc. acquired Vixen Pharmaceuticals for \($1.25\) billion cash, in a merger. Vixen had two promising products for treating common infections under review by the U.S. Food and Drug Administration. The balance sheets of Fiser and Vixen reflect data immediately prior to the acquisition. Fair value information appears for Vixen's reported assets and liabilities.

\($1\) billion of the purchase price was allocated to previously unreported in-process research and development attributed to Vixen’s products under development. The purchase price was low due to Vixen’s poor performance in previous years—Vixen reported a retained earnings deficit of \($2.15\) billion as of the date of acquisition. To close the deal, Fiser agreed to pay the former owners of Vixen \($2\) for every dollar of total revenue above \($50\) million reported on sales of Vixen’s products over the next two years. This payment, if made at all, would occur at December 31, 2016. Fiser expects that there is only a 10 percent chance the payment will be made, as follows:

Required

a. Calculate the present value of the earnout agreement, using a 15 percent discount rate.

b. This acquisition is a bargain purchase. Calculate the gain on acquisition reported by Fiser.

c. Prepare the entry Fiser made to record the acquisition.

d. Prepare Fiser's post-combination balance sheet.

Transcribed Image Text:

(in thousands) Current assets Property, plant and equipment.. Patents.. Total assets Fiser, Inc. Vixen Pharmaceuticals Book Value Book Value Fair Value $ 5,000,000 60,000,000 200,000 10,000,000 $ 200,000 5,000,000 10,000,000 $75,000,000 $35,000,000 25,000,000 500,000 $10,700,000 $ 7,850,000 5,000,000 (2,150,000) $10,700,000 3,000,000 $8,200,000 $7,850,000 Liabilities.. Capital stock Retained earnings 15,000,000 Total liabilities and equity. $75,000,000